Methylthioadenosine phosphorylase (MTAP) is an important enzyme used for the salvage of adenine and methionine. Cells lacking this enzyme are expected to be sensitive to purine synthesis inhibitors and/or methionine starvation. We reported previously that the MTAP gene is deleted in adult T cell leukemia (ATL) cells. In the present study, we expanded our series and used a real-time quantitative PCR assay for accurate diagnosis of the deletion and nine of 65 primary ATL samples (13.8%) were MTAP negative. In spite of this low incidence, ATL cells showed significantly higher sensitivity to L-alanosine, an inhibitor of de novo adenosine monophosphate (AMP) synthesis, than normal lymphocytes, suggesting that the MTAP gene is inactivated not only by deletion but also by other mechanisms. Indeed, a real-time quantitative RT-PCR assay disclosed that primary ATL cells had significantly lower MTAP mRNA expression than normal lymphocytes. Since MTAPnegative ATL cell lines also showed much higher sensitivity to L-alanosine than MTAP-positive ATL cell lines, we used these cell lines to investigate whether it is possible to develop selective therapy targeting MTAP deficiency. A substrate of MTAP, methylthioadenosine (MTA) or its substitutes rescued concanavalin A (Con A)-activated normal lymphocyte proliferation from L-alanosine toxicity. All the compounds except 5Ј-deoxyadenosine, however, also caused the undesirable rescue of MTAPnegative ATL cell lines. 5Ј-Deoxyadenosine had the desired ability to rescue hematopoietic progenitor cells without rescuing ATL cell lines. These results support the rationale for a chemotherapy regimen of L-alanosine combined with 5Ј-deoxyadenosine rescue in MTAP-deficient ATL.
Introduction
Adult T cell leukemia (ATL) is a unique lymphoproliferative disease of mature helper T cell origin 1, 2 which is caused by human T lymphotropic virus type-I (HTLV-I). [3] [4] [5] Because of its clinical diversity, ATL is subclassified into four subtypes, acute, lymphoma, chronic and smoldering. 6 The prognosis of the aggressive subtypes of ATL, namely acute and lymphoma, is extremely poor, and their median survival time and 3-year survival rate were only 13 months and 21.9%, respectively, even in the most recent clinical trial. 7 There is no standard chemotherapy that provides a high cure rate, and establishment of a new treatment strategy is needed. The deletion of cell cycle regulatory genes p16 INK4a and p15 INK4b8, 9 occurs frequently in ATL, and is closely associated with its poor prognosis. Patients with deletions of these tumor suppressor genes are exclusively clustered in aggressive ATL and show signifi- cantly shorter survival time than those patients in whom both genes are preserved. 10, 11 The methylthioadenosine phosphorylase (MTAP) gene resides on chromosome 9p21 close to the p16 and p15 genes. Interestingly, co-deletion of the MTAP gene along with these genes has been reported in several types of malignancies including ATL. [12] [13] [14] MTAP, a ubiquitous enzyme present in all normal tissues, plays a major role in the salvage of both adenine and methionine. MTAP cleaves 5Ј-deoxy-5Ј methylthioadenosine (MTA) into adenine and 5-methylthioribose-1-phosphate (MTR-1-P). 15, 16 Then, the adenine is salvaged to generate adenosine monophosphate (AMP), and the MTR-1-P is converted to methionine ( Figure 1 ). Accordingly, cells lacking this enzyme are totally dependent on de novo AMP synthesis and the exogenous methionine supply. L-alanosine, an amino acid analogue derived from Streptomyces alanosinicus, inhibits de novo AMP synthesis from inosine monophosphate (IMP) (Figure 1) . 17, 18 The anti-tumor activity of L-alanosine was first shown more than two decades ago. 19, 20 However, it has never been used as a practical agent because of its adverse effects and moderate anti-tumor activity. Since L-alanosine interferes with de novo AMP synthesis, and cells lacking MTAP cannot salvage adenosine, MTAP-deficient cells should be sensitive at low doses at which MTAP-positive cells are hardly affected. The diagnosis of MTAP gene deletion must be accurate if we are actually to apply this treatment strategy to patients. We therefore developed a real-time quantitative PCR assay and compared the results with those obtained by the Southern blot assay. 21 We expanded this series in the present study. Moreover, we performed real-time RT-PCR to measure MTAP mRNA quantitatively. We found that the majority of primary ATL cells showed higher L-alanosine sensitivity and had lower amounts of MTAP mRNA than normal lymphocytes. Similarly, MTAP gene-negative ATL cell lines also showed much higher sensitivity to L-alanosine than MTAP gene-positive ATL cell lines. It is theoretically possible to rescue MTAP enzyme-positive cells from L-alanosine toxicity by supplementation of MTA or its substitutes. MTAP-positive cells should be able to get enough adenine from these compounds for their survival. We tested this hypothesis and tried to find an appropriate compound that alleviates L-alanosine toxicity in MTAPpositive normal cells.
Materials and methods

Primary ATL cells and ATL cell lines
Heparinized peripheral blood or lymph nodes were obtained from 65 patients with ATL (42 acute type, 17 chronic type and six lymphoma type) after informed consent. Mononuclear Metabolic pathway involving MTAP and the site of action of L-alanosine. There are two pathways for AMP synthesis, ie de novo and salvage pathways. MTA is cleaved by MTAP into adenine and MTR-1P, and the adenine is salvaged to form AMP. L-alanosine selectively inhibits the de novo AMP synthetic pathway. cells were separated by Lymphoprep (Axis-Shield, Oslo, Norway) density gradient centrifugation and used as primary ATL cells. All samples contained greater than 80% ATL cells as judged morphologically. Five ATL cell lines, SO4, ST1, KK1, KOB and OMT, established in our laboratory, were also used. Their primary ATL cell origin was confirmed previously by the concordance of the integration site(s) of HTLV-I proviral DNA and/or the rearrangement profile of the T cell receptor (TCR) ␤-chain gene. [22] [23] [24] [25] The MTAP gene consists of eight exons.
26 SO4 and ST1 have lost exons 5 to 8 and KK1 has lost all exons. 14 The preservation of all exons in KOB and OMT was confirmed in the present study (data not shown). These cell lines were maintained in RPMI 1640 medium (GibcoBRL, Grand Island, NY, USA) containing 10% FCS with 0.25 Takeda unit/ml of recombinant IL-2 (kindly provided by Takeda Pharmaceutical, Tokyo, Japan). All cell lines were tested for Mycoplasma infection and were negative.
Cell proliferation assay
Primary ATL cells and unstimulated normal lymphocytes (2 ϫ 10 5 cells/100 l/well) were cultured with various concentrations of L-alanosine in the presence of IL-2 in 96-well tissue culture plates for 4 days, and their proliferation status was evaluated using Cell Titer 96 AQueous (Promega, Madison, WI, USA) according to the manufacturer's protocol. L-alanosine was a generous gift from Triangle Pharmaceuticals (Durham, NC, USA) and was dissolved in sodium hydroxide (NaOH). ATL cell lines (3 ϫ 10 4 cells/100 l/well) were cultured under the same conditions, but their proliferation status was examined on day 3. MTA, 5Ј-deoxyadenosine and three S-adenosyl-L-methionine (SAM) substitutes, SAM chloride salt (SAM-Cl), SAM iodide salt (SAM-I) and SAM p-toluenesulfonate salt (SAM-p-toluene) (Sigma-Aldrich, St Louis, MO, USA) were dissolved in dimethyl sulfoxide (DMSO) and various concentrations of each compound were added to culture solution to examine whether they could rescue MTAP-positive normal cells from L-alanosine toxicity. Exactly the same final concentrations of NaOH and/or DMSO as those present in cultures treated with these compounds were added to control cell cultures. Concanavalin A (Con A, 5 g/ml)-activated lymphocytes and bone marrow hematopoietic progenitor cells obtained from healthy adult volunteers were used for this rescue experiment. Bone marrow cells were plated in Methocult GF H4434 (Stemcell Technologies, Vancouver, Canada), and the number of granulocyte-macrophage colonies (CFU-GM) and erythroid colonies (BFU-E) were counted. All cell culture experiments were performed in triplicate.
Southern blot analysis
Southern blot analysis was performed to examine MTAP gene deletion according to the method described elsewhere.
14 In brief, genomic DNA was digested with EcoRI, separated on a 1% agarose gel, transferred to a positively charged nylon membrane (Roche Diagnostics, Mannheim, Germany), and hybridized with the probe for the MTAP gene. 26 A digoxigenin-labeled probe was used instead of a 32 P-labeled probe in the present assay. The membrane was treated with an antidigoxigenin antibody conjugated with alkaline phosphatase (Roche Diagnostics), and the enzyme activity was changed to a light signal by CDP-Star (Roche Diagnostics) and detected by exposure to film. Since primary ATL samples sometimes contain considerable numbers of normal lymphocytes, the signal intensities of the bands corresponding to the MTAP exons were compared with that of the band corresponding to the MTAP pseudogene, which resides on a different chromosome, 26 and thereby the deletion of the MTAP gene could be accurately evaluated.
Real-time quantitative polymerase chain reaction (PCR)
Real-time PCR was performed using the LightCycler rapid thermal cycler system (Roche Diagnostics). The reaction was performed in a total volume of 20 l containing 5 l of DNA (1-2 ng/l) from normal control, primary ATL cells or ATL cell lines, 0.16 l of Taqstart antibody (1.1 g/l) (BD Biosciences Clontech, Palo Alto, CA, USA), 2 l of GC-melt (BD Biosciences Clontech) and 4 l of 25% DMSO (Sigma-Aldrich). LightCycler-DNA Master SYBR Green I (Roche Diagnostics) was used for quantitation of the products. Since deletion of the MTAP gene occurs from exon 8 to exon 1, 14 and it is difficult to judge the deletion of exon 8 by Southern blot analysis, we performed real-time PCR at both exons 1 and 8. The primers used were as follows: for exon 1: 5Ј-GGGGAG GAAGAGGAGGAGTCAAG-3Ј(sense) and 5Ј-AAGAAGAATC GGGCAGGGCGAACC-3Ј(antisense); for exon 8: 5Ј-GCCAA CATGTGAATATCACTGCCTCCTT-3Ј(sense) and 5Ј-ACTAGT GATTTGCTTTTCTTCTGTATTTTGA-3Ј(antisense). Thermal cycling for exon 1 consisted of an initial denaturation at 95°C for 2 min, followed by 45 cycles with 95°C for 0 s (denaturation, touch down method), 58°C for 7 s (annealing), and 72°C for 11 s (extension), and that for exon 8 consisted of an initial denaturation at 95°C for 2 min, followed by 45 cycles of 95°C for 0 s, 63°C for 5 s, and 72°C for 11 s. The results of analysis of MTAP exon 1 using diluted samples of control DNA and the linear standard curve generated therefrom are shown in Figure 2a . The primers used for ␤-globin as an internal control were as follows: 5Ј-ACACAA CTGTGTTCACTAGC-3Ј(sense) and 5Ј-CAACTTCATCCA CGTTCACC-3Ј(antisense). The reaction was started by denaturation at 95°C for 1 min followed by 40 cycles of 95°C for 0 s, 55°C for 5 s, and 72°C for 10 s. The calculated copy numbers of MTAP exon 1 and exon 8 were divided by the copy number of ␤-globin, and the relative values for exon 1 and
Figure 2
Amplification of MTAP exon 1 in control DNA (a), and amplification of MTAP cDNA in MTAP cDNA-containing plasmid (b). Relative fluorescence intensity was plotted against cycle number for each dilution series and linear standard curves were generated from the data. Photographs of agarose gel electrophoresis of the PCR products show single bands with the expected size.
Leukemia exon 8 compared to ␤-globin were obtained. Considering the contamination of normal cells in ATL samples, samples with values less than 0.4 were judged to be MTAP gene negative.
RNA extraction and real-time quantitative RT-PCR
Among the 65 mononuclear cell samples collected for the present study, 21 samples were available for RNA extraction. Total RNA was extracted according to the Isogen protocol (Wako, Osaka, Japan) and treated with DNase (Message Clean Kit; GenHunter Corporation, Nashville, TN, USA) to remove contaminated DNA. The final concentration of RNA was adjusted to 1 g/l, and cDNA was synthesized by using the Thermoscript RT-PCR System (Invitrogen, Carlsbad, CA, USA). One microgram of RNA was incubated with oligo(dT) 20 primer and avian RNase H-minus reverse transcriptase, and 20 l of cDNA product was obtained. The PCR conditions were basically the same as those used in the quantitative PCR assay except for the use of cDNA as template instead of genomic DNA. In a final reaction volume of 20 l reaction, 2.5 l of cDNA from normal control mononuclear cells, 2.5 l of cDNA from primary ATL cells or 1 l of cDNA from ATL cell lines was mixed. The primers used for MTAP cDNA were as follows: 5Ј-GCTCTGTGGCTCGCTTGGTT-3Ј(sense) and 5Ј-AGCCATGCTACTTTAATGTCT-3Ј(antisense). The thermal cycling conditions consisted of an initial denaturation at 95°C for 2 min, followed by 40 cycles of 95°C for 0 s, 65°C for 5 s, and 72°C for 39 s. The primers used for GAPDH cDNA as an internal control were as follows: 5Ј-GGTGAA GGTCGGTGTGAACGGATTT-3Ј(sense) and 5Ј-AATGCC AAAGTTGTCATGGATGACC-3Ј(antisense). The reaction was started at 95°C for 2 min followed by 40 cycles of 95°C for 0 s, 65°C for 5 s, and 72°C for 20 s.
For the preparation of an external control for MTAP mRNA, a known amount of plasmid containing MTAP cDNA was extracted using a QIAprep Miniprep Kit (Qiagen, Tokyo, Japan), linearized by treatment with NaeI (Takara, Shiga, Japan) and subjected to electrophoresis (1% Seakem GTG agarose, 1 ϫ TAE) (BioWhittaker Molecular Applications, Rockland, ME, USA). Then the region of the gel containing the plasmid was cut out and treated with a Geneclean Kit (Qbiogene, Carlsbad, CA, USA) for purification of the plasmid. The concentration of purified plasmid was quantified using a PicoGreen ds DNA Quantitation Kit (Molecular Probe, Eugene, OR, USA). The copy number of the MTAP cDNA was calculated, and serially diluted samples were obtained. Relative fluorescence intensity was plotted against the number of cycles, and a linear standard curve generated from a starting copy number of 3.78 ϫ 10 2 to 3.78 ϫ 10 6 was made ( Figure  2b ). The expression of MTAP mRNA was standardized by dividing the copy number of MTAP by the copy number of GAPDH to compensate for variations in quantity or quality of starting mRNA as well as for differences in reverse transcriptase efficiency. Then the values were multiplied by 10 3 (copy number of MTAP ϫ 1000/copy number of GAPDH), and the resulting values were used to express the level of MTAP mRNA. Table 1 . Although it has been reported that p15-and/or p16-gene-negative patients are clustered in the acute subtype, there was no significant correlation between MTAP gene deletion and ATL subtype.
Results
MTAP gene in primary ATL cells
Sensitivity of ATL cells to L-alanosine
Cells were cultured with various concentrations of L-alanosine. There was a clear difference between normal lympho- 
MTAP mRNA in ATL cells and L-alanosine sensitivity
Since MTAP-positive primary ATL samples also showed high L-alanosine sensitivity, we examined MTAP mRNA by real- median: 2.37, P ϭ 0.0007) (Figure 6b) . The values of three MTAP gene-negative patients were all less than 1.0 (0.39, 0.52 and 0.90). Next, we divided patients into two groups according to the grade of MTAP mRNA expression, high-MTAPmRNA (n ϭ 10) and low-MTAP-mRNA (n ϭ 10), and examined whether there was a difference in sensitivity to L-alanosine between the two groups ( Figure 7) . Although it was not significant, there was a trend for the low-MTAP-mRNA group to show higher L-alanosine sensitivity than high-MTAP-mRNA group (IC 20 : 41 Ϯ 43 vs 127 Ϯ 137) (P ϭ 0.0724). The standardized MTAP mRNA expression of MTAP-positive cell lines KOB and OMT was very high, being 8.6 and 7.2, respectively, but those of MTAP-negative cell lines SO4, ST1 and KK1 were all 0 (undetectable).
Rescue of normal cells from L-alanosine toxicity
Using MTA and related compounds, we next examined whether these compounds could rescue MTAP-positive normal cells from L-alanosine toxicity. In experiments using Con A-activated lymphocytes, MTA rescued lymphocytes almost completely, and 5Ј-deoxyadenosine, SAM-Cl and SAM-I rescued up to 80%, but SAM-p-toluene did not rescue the lymphocytes and was itself toxic instead ( Figure 8 ). To determine whether specifically rescued MTAP-positive normal cells but not MTAP-deficient tumor cells, we performed the same experiments using an MTAP gene-negative ATL cell line. As shown, all of these compounds except 5Ј-deoxyadenosine unexpectedly rescued the ATL cell line (Figure 8) . Therefore, 5Ј-deoxyadenosine was the only agent with the desired specificity, and we next examined whether this compound rescues the growth of hematopoietic stem cells. L-alanosine suppressed CFU-GM and BFU-E colony formation with IC 50 s of 8.4 and 44.5 M, respectively (Figure 9a) , and 5Ј-deoxyadenosine clearly alleviated the toxicity (Figure 9b ). 
Discussion
A therapeutic approach targeting MTAP-enzyme deficiency was first reported by Kamatani et al. 27 They examined the MTAP enzyme activity in various cancer cell lines by using 5Ј-chloroadenosine as a substrate. When the cell lines were cultured with methotrexate (MTX), an antifolate which inhibits de novo purine synthesis like L-alanosine, only the MTAP enzyme activity-negative cell lines were effectively killed,
Figure 7
MTAP mRNA expression and L-alanosine sensitivity. Patients were divided into two groups according to MTAP mRNA expression, high-MTAP-mRNA group (n ϭ 10) and low-MTAP-mRNA group (n ϭ 10), and their L-alanosine sensitivities were compared. There was a tendency for the low-MTAP-mRNA group to have a higher sensitivity than the high-MTAP-mRNA group (IC 20 : 41 Ϯ 43 vs 127 Ϯ 137) (Mann-Whitney U test, P ϭ 0.0724).
while MTAP enzyme activity-positive cell lines survived if MTA was supplied. Soon after, MTAP protein deficiency or MTAP gene deletion was found in primary tumor cells such as gliomas, lung cancers and acute leukemias. 13, [28] [29] [30] This discovery supports the idea that MTAP-deficient malignant cells could be selectively killed by MTX. However, as far as we know, this idea has never been applied in clinical chemotherapy using MTX. Since L-alanosine exclusively blocks AMP synthesis, in contrast to MTX, which also inhibits pyrimidine synthesis, L-alanosine is more specific than MTX as an agent targeting MTAP deficiency. Phase I and phase II clinical trials of L-alanosine alone or L-alanosine in combined treatment with other anti-neoplastic agents were conducted for advanced cancers and leukemias during the early 1980s.
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Figure 8
Rescue of Con A-activated lymphocytes from L-alanosine toxicity. Cells were cultured with L-alanosine (100 M) in the absence or presence of various concentrations of MTA and MTA substitutes. MTA rescued lymphocytes almost completely, and 5Ј-deoxyadenosine, SAM-CI and SAM-I rescued up to 80%, but SAM-p-toluene did not rescue the lymphocytes. All these compounds except 5Ј-deoxyadenosine (upper right corner) also rescued MTAP-negative cell line SO4.
However, these trials were performed without consideration of MTAP enzyme activity or MTAP gene status, and the studies did not produce favorable results and were discontinued.
Recently, frequent deletion of the MTAP gene (more than 30%) was found in T cell acute lymphoblastic leukemia (T-ALL), and the efficacy of L-alanosine treatment in this disease was investigated using T-ALL cell lines. 13 In contrast to our results, however, L-alanosine equally inhibited the growth of both MTAP-negative and MTAP-positive cell lines with IC 50 from 6 to 10 M. The same authors also examined clinical samples, and showed that MTAP-negative T-ALL cells were more sensitive than MTAP-positive T-ALL cells. 36 Intriguingly, they found that some MTAP-positive T-ALL cells also showed very high sensitivity to L-alanosine, equivalent to that of MTAP-negative cells. This result raises the possibility that changes in genes other than MTAP are responsible for such differences in sensitivity. Hori et al 37 however, confirmed that MTAP deficiency contributes directly to the sensitivity of cancer cells to purine or methionine depletion using paired cell lines that had an identical genotype except for MTAP. Another possibility is that the presence of the MTAP gene does not always lead to the production of MTAP mRNA and MTAP protein. The MTAP gene of the T-ALL samples having high L-
Leukemia
Figure 9
Rescue of hematopoietic stem cells from L-alanosine toxicity. Inhibition of colony formations by L-alanosine (a), and alleviation of the toxicity by 5Ј-deoxyadenosine (b) are shown. Both CFU-GM and BFU-E were completely inhibited at concentrations more than 100 M, and CFU-GM was more sensitive than BFU-E with their IC 50 of 8.4 and 44.5 M, respectively. Although 5Ј-deoxyadenosine itself acted somewhat toxic, it definitely alleviated the toxicity of Lalanosine (column 2 vs 4, Mann-Whitney U test, P ϭ 0.0463 for CFU-GM, P ϭ 0.0369 for BFU-E).
alanosine sensitivities may be inactivated by methylation, and thus may produce very little MTAP mRNA. It has been reported that although deletion of the p16 gene is a rare event in multiple myeloma (MM), 41 of 101 MM patients (40.5%) had methylation of the exon E1 alpha of the p16 gene. 38 Therefore, it is essential to examine MTAP mRNA or MTAP protein expression in order to evaluate this therapeutic approach. In the present study, we found that although the incidence of MTAP gene deletion was only 13.8%, most primary ATL samples expressed lower amounts of MTAP mRNA than normal lymphocytes. Resting normal lymphocytes express small amounts of MTAP mRNA (less than 100th the level of GAPDH mRNA), which increase approximately 10-fold after activation with Con A (data not shown). The level of MTAP mRNA relative to control GAPDH mRNA also increases two-to three-fold after activation with Con A, suggesting that proliferating cells re-use adenine and methionine effectively by up-regulating production of this enzyme. ATL cells originate from activated T cells, which are characterized by the constitutive expression of IL-2R-alpha (CD25). Nevertheless, the amount of MTAP mRNA in primary ATL cells was lower than that in resting normal lymphocytes. This result indicates that ATL cells derive AMP mostly through the de novo AMP synthetic pathway rather than through the salvage pathway. This characteristic makes such cells good targets for this treatment strategy, and indicates that patients with low MTAP mRNA expression without MTAP gene deletion should also benefit from L-alanosine treatment.
In the present study, primary ATL cells from the low-MTAPmRNA group showed a tendency to be more sensitive to Lalanosine than the cells from the high-MTAP-mRNA group, as expected. However, primary ATL cells were far less sensitive to L-alanosine than MTAP gene-negative ATL cell lines, even though they were from the low-MTAP-mRNA group. We think this is because most primary leukemia cells in the peripheral blood are in a dormant phase and do not need as much adenine and methionine as rapidly proliferating cells. We believe that there are rapidly proliferating ATL cells in ATL patients, probably in the lymph nodes and those cells are the target of this therapy. These rapidly proliferating cells should be as sensitive as MTAP gene-negative ATL cell lines.
The ideal treatment would kill malignant cells exclusively, leaving normal cells intact. Since normal cells have MTAP enzyme, L-alanosine toxicity will be reduced or even negated if sufficient amounts of MTAP substrates are supplied. By using hematopoietic stem cell colony formation as a marker, the ability of 5Ј-deoxyadenosine to relieve the bone marrow toxicity of L-alanosine has been tested. 39 Formation of CFU-GM and BFU-E colonies was suppressed by incubation with 5 M or greater concentrations of L-alanosine, and the colony formation was restored when 5Ј-deoxyadenosine was supplied. In the present study, we evaluated not only 5Ј-deoxyadenosine but also MTA and three SAM salts. SAM, a precursor of MTA called SAMe or Sammy, is an unstable metabolic intermediate that serves as a donor of methyl and aminopropyl groups to a variety of acceptor molecules. After discovery of its stable salts and the development of an enteric coated oral formulation, this compound has become commercially available, and is used for the treatment of arthritis, fibromyalgia, liver disease, and migraine headaches. 40 Since these have been used in the practice of internal medicine, it would be convenient if they met our requirements. However, MTA and all of the SAM salts tested disappointingly rescued MTAPnegative ATL cell lines. We do not know at present how MTAP-negative cells were able to cleave these compounds without the participation of MTAP. There may be an alternative pathway for metabolizing MTA and SAM, or these compounds may be unstable and may easily donate adenine to cells. SAM salts are quite popular non-prescription drugs, and many people are thought to be taking them as a kind of health food nowadays. If patients undergoing clinical trials of Lalanosine treatment continue to take them, the results may be distorted. The present results raise this possibility and suggest the need for caution in this respect. We found that only 5Ј-deoxyadenosine met our specificity requirements, ie it reduced the toxicity of L-alanosine in both Con A-activated lymphocyte proliferation and CFU-GM and BFU-E colony formation tests without rescuing MTAP-negative ATL cell lines. 5Ј-Deoxyadenosine itself, however, was somewhat toxic to normal cells and did not rescue cells completely. The 5Ј-deoxyadenosine we used may have become contaminated with some cell-toxic agent(s) during its purification process. We may be able to achieve a better rescue if we could use a higher concentration of more purified 5Ј-deoxyadenosine. We used the same molecular concentration of 5Ј-deoxyadenosine as L-alanosine in this study. In further studies, a compound superior to 5Ј-deoxyadenosine should be sought.
In conclusion, we found that the incidence of MTAP gene deletion in ATL patients was low (13.8%), but most primary ATL cell samples showed significantly lower MTAP mRNA expression and higher L-alanosine sensitivity than normal lymphocytes irrespective of their MTAP gene status. As far as we know, this is the first report showing low MTAP mRNA production in MTAP gene-positive malignant cells. Moreover, we found that, among all compounds tested here or previously, 5Ј-deoxyadenosine had the best ability to rescue normal cells from L-alanosine toxicity. Since actively proliferating cells need large amounts of adenine and methionine, a therapeutic approach combining L-alanosine and MTAP substrates may be effective against rapidly growing cells.
